ISMIVS Newsletter September&October, 2022 Newsletter ISMIVS

ISMIVS Newsletter September&October, 2022

Newsletter 2022 Sep & Oct
2022年9&10月简报

About Us 国际微无创医学会简介

The International Society of Minimally Invasive and Virtual Surgery (ISMIVS, previously known as International Society of Minimally Invasive and Noninvasive Medicine) was founded in July 2013 at the gala of the 1st Yangtze International Summit of Minimally Invasive and Noninvasive Medicine in Chongqing, China. ISMIVS envisions to accelerating the progress in minimally invasive and noninvasive medicine by promoting research, education, communication, and international collaboration.
国际微无创医学会（ISMIVS）是在 2013 年 7 月在中国重庆召开的第一届国际微无创医学长江高峰论坛上宣布成立的，旨在通过学术研究、教育、交流以及国际合作加快微无创医学的发展。

Become a member 注册成为会员 >

The Personality in the Medical Education World 医学教育界的大人物

From the 2020 July issue of our ISMIVS Newsletter, we would like to introduce some pioneers in the field of minimally-invasive and noninvasive medicine. They are not only prestigious in their area but also willing to share their experience and ideas with younger doctors, hence making a significant contribution to medical education. This issue features Prof. Wang Zhibiao who received the Inaugural Clinical Award from the Focused Ultrasound Foundation in September 2022 (article source: https://symposium.fusfoundation.org/2022/09/13/professor-zhibiao-wang-to-receive-inaugural-clinical-adoption-award/).
从 2020 年 7 月刊开始，国际微无创医学会将为大家介绍微无创医学领域的一些领军人物。他们不仅在各自的领域享负盛名，而且非常乐意与年轻医生分享他们的经验、理念和想法，从而为医学教育做出了巨大的贡献。本期月刊要介绍的是2022年9月获美国聚焦超声外科基金会颁发的“临床应用奖”的医学专家王智彪教授（文章来源：https://symposium.fusfoundation.org/2022/09/13/professor-zhibiao-wang-to-receive-inaugural-clinical-adoption-award/）。

Prof. Wang Zhibiao
Director
State Key Laboratory of Ultrasound in Medicine and Engineering
Chongqing Medical University
重庆医科大学超声医学工程国家重点实验室主任
王智彪教授

Director of National Engineering Research Center of Ultrasound Medicine
Founder & Chairman of Chongqing Medical Focused Ultrasound Technology Development Co., Ltd.
超声医疗国家工程研究中心主任
重庆海扶医疗科技股份有限公司创始人及董事长

Professor Zhibiao Wang, MD, PhD, is the Foundation’s inaugural Clinical Adoption Award recipient. The award recognizes an individual dedicated to advancing the field of focused ultrasound and whose efforts have led to a significant number of patient treatments.
王智彪教授，医学博士，被授予国际超声聚焦基金会（FUS Foundation）首次设立的“临床应用奖”。该奖项旨在表彰致力于推动聚焦超声领域发展，同时患者治疗量最多的优秀代表。
In 1999, Prof. Wang founded Chongqing Haifu Medical Technology Co. Ltd., and he now serves as the president and chairman. He leads the company’s research in the fields of device development, clinical application, and marketing. In1999, he developed the company’s – and China’s – first high-intensity focused ultrasound therapeutic system, which has been exported to 28 countries and regions and has collectively treated more than 200,000 patients worldwide. The device is used to treat malignant tumours such as liver cancer, pancreatic cancer, breast cancer, osteosarcoma, soft tissue sarcoma, and a wide range of benign tumours such as uterine fibroids and adenomyosis.
王教授于 1999 年创立了重庆海扶医疗科技有限公司，目前兼任公司总裁和董事长，引领海扶专注于设备开发、临床应用和市场营销等领域的研究。1999 年，他开发了海扶首台——也是中国首台——高强度聚焦超声肿瘤治疗系统，该设备已出口到 28 个国家和地区，在全球治疗患者 20 万余例。该设备可用于治疗恶性肿瘤，如肝癌、胰腺癌、乳腺癌、骨肉瘤、软组织肉瘤，以及各种良性肿瘤，如子宫肌瘤和腺肌症。
Prof. Wang’s career in therapeutic ultrasound has spanned 34 years. He has made pioneering contributions to the field of ultrasound therapy, including breakthroughs in basic research, large medical equipment development, clinical applications, and industry standards.
王教授已深耕治疗性超声领域 34 年有余。他在超声治疗领域做出了开创性的贡献，包括在基础研究、大型医疗设备开发、临床应用和行业标准方面的突破。
He is a Professor of Medicine and leads the State Key Laboratory of Ultrasound in Medicine and Engineering at Chongqing Medical University in China.
作为医学教授，他是中国重庆医科大学超声医疗工程国家重点实验室的主任。
His contributions to therapeutic ultrasound research have garnered major funding grants and second prize in both the National Technology Invention Award and the National Science and Technology Progress Award. He has published more than 50 SCI papers in leading journals in the field of ultrasound medicine.
他领导的治疗性超声方面的科研项目获得了多次国家级立项资助，并荣获中国国家技术发明奖和国家科学进步奖二等奖。此外，他在超声医学领域的权威杂志上累计发表 50 余篇SCI论文。
“Dr Wang is a pioneer in the development of focused ultrasound as a revolutionary, noninvasive therapy and its commercialization,” said Foundation Chairman, Neal F. Kassell, MD. “The company he founded is a leading manufacturer of focused ultrasound equipment, and he has had an immeasurable impact on the technology’s trajectory from idea to its adoption as a global standard of care for a wide variety of serious medical disorders.”
国际超声聚焦基金会主席尼尔-卡塞尔（Neal F. Kassell）博士说道：“聚焦超声是一种革命性的无创疗法，而王智彪医生则是推动该疗法不断发展和商业化的先驱者。他创办的公司是世界领先的聚焦超声设备制造商。从创意之初到如今被采纳为治疗各种严重疾病的全球标准，他对这项技术的发展轨迹有着不可估量的影响”。
Prof. Wang earned his MD/Ph.D degrees from Chongqing Medical University and has been practising as an ObGyn specialist.
王教授在重庆医科大学获得医学博士学位，随后作为妇产科专家开启了他的执业生涯。

Read his research in focused ultrasound:

https://pubmed.ncbi.nlm.nih.gov/25609456/

阅读王教授在聚焦超声方面的文章：

https://pubmed.ncbi.nlm.nih.gov/25609456/

Case Studies 病例分享

While there are clear limitations to the methodology of case studies in the determination of treatment protocol and establishment of new trials, the observation of a single patient can add to our understanding of aetiology, pathogenesis, natural history, treatment option and complications to promote the medical development of a particular disease, and to the clinical practice of potential junior investigators.
尽管病例研究方法在确定治疗方案、组织新的临床试验方面存在明显局限性，但对单个病例的观察研究可以帮助我们了解病因、发病机制、自然病程、治疗方法及并发症，从而促进特定疾病的医学发展，并助益初级研究人员的临床实践。
The case below was shared by Sevellaraja Supermaniam, former President of APAGE, a Consultant Obstetrician and Gynecologist at Mahkota Medical Center, Melaka, Malaysia, on the 2022 APAGE-ISMIVS HIFU Series Webinars EP4.
本期病例由 APAGE 往届主席、马来西亚马六甲州仁爱医院妇产科顾问医师塞尔瓦在 2022 年国际微无创医学会（ISMIVS）与亚太妇产科内视镜暨微创治疗医学会（APAGE）联合会议第四期线上研讨会上分享。

Patient Info 患者信息
35yr old lady married 5 years with no children Severe dysmenorrhea and heavy menses
Underwent IVF with 2 embryos in 2019 1 embryo was transferred in 2021 Did not conceive
Given GnRH analogue On transanemic acid to control bleeding A 16 weeks size uterus
35 岁女性，结婚五年无法怀孕严重痛经、月经量过多
2019 年植入两枚胚胎 2021 植入一枚胚胎未能怀孕
曾用 GnRH 类似物治疗服用传明酸控制月经量子宫达孕 16 周大小

Achieving 71.8% reduction in volume of uterus.
Currently 9 weeks pregnant.
治疗后子宫尺寸缩小 71.8 %。
目前怀孕 9 周

Watch the whole lecture >

Notice 通知

2022 APAGE-OGSM-ISMIVS Conference for
Minimally Invasive and Noninvasive Surgery (Malaysia)
2022 年国际微无创医学会（ISMIVS）与亚太妇产科内视镜暨微创治疗医学会（APAGE）
马来西亚妇产科学会（OGSM）联合会议
暨 2022 年马来西亚微无创手术大会

Nowadays, minimally-invasive and non-invasive therapies, exemplified by the ablation of tumours with less harm to patients, are the trend of modern medical development. This year, joining the hands of Asia-Pacific Association for Gynecologic Endoscopy and Minimally Invasive Therapy (APAGE), Obstetrical & Gynecology Society of Malaysia (OGSM), International Society of Minimally Invasive and Virtual Surgery (ISMIVS) is going to convene a regional conference in Melaka, Malaysia on November 13, 2022, addressing the topic of Laparoscopic Surgery and High Intensity Focused Ultrasound (HIFU) therapy.
如今，微无创治疗是现代医学发展的趋势，比如，对患者伤害较小的肿瘤消融法。今年，亚太妇产科内窥镜和微创治疗医学会（APAGE）、马来西亚妇产科学会（OGSM）、国际微无创医学会（ISMIVS）将于 2022 年 11 月 13 日在马来西亚马六甲召开区域性大会，探讨腹腔镜手术和高强度聚焦超声（HIFU）。
With the envision to accelerate the development of minimally-invasive and non-invasive medicine, we hope this major event could provide doctors and patients with novel and better solutions to disease management.
以加快微无创医学发展为重要目标，我们希望本次会议能够为医生和患者提供更好、更先进的疾病管理方案。
Looking forward to seeing you in Melaka!
期待在马六甲见到您!

Moments and playback of this event:

本次会议的更多精彩片段，请关注：

Follow us on LinkedIn or Facebook or Youtube

Program >

HIFU Special Issue 高强度聚焦超声特刊

US-guided high-intensity focused ultrasound (HIFU) of abdominal tumours: outcome, early ablation-related laboratory changes and inflammatory reaction. A single-centre experience from Germany
超声引导的高强度聚焦超声 (HIFU)治疗腹部肿瘤：结果、早期消融相关实验室变化和炎症反应——
来自德国的单治疗中心

The aim of this study is to evaluate if a HIFU-induced early sterile inflammatory reaction is initiated after the ablation of uterine fibroids (UF) and pancreatic carcinoma (PaC) which might contribute to the therapeutic effect.
本文研究的目的是评估在切除子宫肌瘤 (UF) 和胰腺癌 (PaC) 后是否会引发 HIFU 诱导的早期无菌炎症反应，这可能有助于治疗效果。
A hundred patients with PaC and 30 patients with UF underwent US-guided HIFU treatment. An early post-ablation inflammatory response was observed in both groups with a significant increase of leukocytes, CRP and LDH within the first 20 h after HIFU. Interestingly, IL-6 was increased at 20 h after HIFU in PaC patients. A significant reduction of tumor volumes was observed during one-year follow-up (p < .001) for both tumor entities demonstrating effective treatment outcomes.
100 名 PaC 患者和 30 名 UF 患者接受了超声引导下的 HIFU 治疗。两组均观察到早期消融后炎症反应，HIFU 后前 20 小时内白细胞、CRP 和 LDH 显着增加。有趣的是，在 PaC 患者中，HIFU 后 20 小时 IL-6 增加。在一年的随访中观察到肿瘤体积显着减少（p < .001），两种肿瘤实体均显示出有效的治疗结果。
Tumor ablation with HIFU induces an early sterile inflammation that might serve as a precondition for long-term tumor immunity and a sustainable therapeutic effect.
HIFU 肿瘤消融可诱导早期无菌炎症，这可能是长期肿瘤免疫和可持续治疗效果的先决条件。